MannKind (NASDAQ:MNKD) shares rose 13% premarket on Monday after the U.S. drug regulator cleared its clofazimine inhalation ...
The new desktop Inhalation Exposure system offers the ... The heart of the system is the nebulizer-venturi unit into which the suspension is introduced. Air pressure atomizes the suspension ...
The Inhalation Exposure System provides reproducible ... The heart of the system is the nebulizer-venturi unit into which the suspension is introduced. Air under pressure atomizes the suspension ...
Internally, MannKind is developing clofazimine inhalation suspension and nintedanib DPI for nontuberculous mycobacterial lung disease (NTM-LD) and IPF, respectively. In Q4, MannKind recorded $76. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results